NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with bes ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a ...

Learn more about whether Kymera Therapeutics, Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ ...

Learn more about whether Sarepta Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...